KBC Group NV Decreases Holdings in Cerner Co. (CERN)

Marco Green
December 11, 2017

Acrospire Investment Management LLC now owns 1,800 shares of the company's stock worth $120,000 after acquiring an additional 900 shares during the period. With 2.95 million shares average volume, it will take short sellers 4 days to cover their CERN's short positions. The stock increased 1.65% or $0.235 during the last trading session, reaching $14.445. About 284,260 shares traded. Cerner Corporation (NASDAQ:CERN) has risen 19.54% since December 9, 2016 and is uptrending. It has outperformed by 0.99% the S&P500. Echo Street Cap Llc has invested 0.23% in Cerner Corporation (NASDAQ:CERN). The company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.01). CERN's profit will be $196.12M for 29.78 P/E if the $0.59 EPS becomes a reality. Its down 14.59% from 13.44 million shares, reported previously. (NASDAQ:PAAS), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. BidaskClub raised Cerner from a "sell" rating to a "hold" rating in a research report on Saturday, August 19th. Nasdaq.com's news article titled: "Bear Of The Day: Cerner Corp (CERN)" with publication date: December 07, 2017 was also an interesting one. The firm has "Buy" rating by Topeka Capital Markets given on Friday, May 6. Finally, KeyCorp reiterated a "buy" rating and issued a $76.00 target price on shares of Cerner in a research report on Friday, September 22nd. The legal version of this piece of content can be accessed at https://weekherald.com/2017/12/09/cerner-corporation-cern-stock-rating-reaffirmed-by-stifel-nicolaus.html. The company now has a consensus rating of "Hold" and an average price target of $69.50. Jefferies Group set a $79.00 price target on shares of Cerner and gave the stock a "buy" rating in a research note on Friday, October 13th. Robert W. Baird maintained the shares of CERN in report on Wednesday, June 7 with "Hold" rating. The stock of Cerner Corporation (NASDAQ:CERN) has "Top Pick" rating given on Thursday, January 7 by RBC Capital Markets. The firm has "Buy" rating given on Friday, October 27 by Piper Jaffray. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cerner in the 2nd quarter valued at about $44,524,000. It also upped Fidelity (FENY) stake by 20,860 shares and now owns 57,429 shares.

The stock decreased 1.82% or $0.03 during the last trading session, reaching $1.62. Its down 0.06, from 0.93 in 2017Q1. It dropped, as 39 investors sold CERN shares while 243 reduced holdings. 74 funds opened positions while 170 raised stakes. TheStreet upgraded shares of Cerner Corporation from a "c+" rating to a "b-" rating in a research report on Monday, April 3rd.

TRADEMARK VIOLATION NOTICE: "Cerner (NASDAQ:CERN) Given Daily Coverage Optimism Rating of 0.30" was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. Cerner Corporation (NASDAQ:CERN) last released its quarterly earnings data on Thursday, April 27th. State Of Wisconsin Invest Board invested in 364,386 shares or 0.08% of the stock.

Greenbrier Partners Capital Management Llc holds 0.22% of its portfolio in Valhi, Inc. for 344,790 shares.

Miles holds 0.82% or 22,972 shares.

CERN has been the subject of a number of recent analyst reports. Comgest Global Investors Sas reported 158,600 shares stake. Its down 1.62, from 2.4 in 2017Q1. Ledyard Retail Bank invested in 4,095 shares or 0.04% of the stock. They expect $0.59 EPS, up 3.51% or $0.02 from last year's $0.57 per share. Royal Comml Bank Of Canada stated it has 1,000 shares or 0% of all its holdings. Professional Advisory Svcs holds 135,764 shares. Morgan Stanley accumulated 464,358 shares. Schwab Charles Mgmt Incorporated reported 937,175 shares. Los Angeles Capital Mngmt And Equity Rech invested in 0% or 3,300 shares. Deutsche Bancshares Ag owns 0% invested in Heat Biologics, Inc. 18,850 are owned by Bartlett Ltd Liability.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company was initiated on Wednesday, October 21 by Avondale. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology created to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product.

Other reports by Click Lancashire

Discuss This Article